PMID- 19895615
OWN - NLM
STAT- MEDLINE
DCOM- 20100629
LR  - 20211020
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 148
IP  - 4
DP  - 2010 Feb
TI  - A comprehensive evaluation of the prognostic significance of 13q deletions in 
      patients with B-chronic lymphocytic leukaemia.
PG  - 544-50
LID - 10.1111/j.1365-2141.2009.07982.x [doi]
AB  - Deletion 13q14 on fluorescence in situ hybridization (FISH) analysis is the most 
      common cytogenetic abnormality in chronic lymphocytic leukaemia (CLL), and is a 
      favourable prognostic biomarker when detected as a sole abnormality. We 
      intensively interrogated clinical outcome in 323 consecutive, untreated CLL 
      patients with isolated 13q- identified within 2 years of diagnosis. We also 
      analyzed outcome in 217 additional patients with deletion 11q22.3 or 17p13.1, or 
      trisomy 12, based on whether these occurred in isolation or in conjunction with 
      13q-. Patients with a heterozygous 13q- and those with a homozygous deletion had 
      similar time to first treatment (TFT) and overall survival (OS). In contrast, a 
      higher percentage of 13q- nuclei was associated with significantly shorter TFT (P 
      < 0.001). The 5-year untreated rate was 79% for patients with isolated 13q- in < 
      or =65.5% of nuclei compared to 38% among those with 13q- in >65.5% of nuclei (P 
      < 0.001). The percentage of nuclei exhibiting 13q- remained an independent 
      predictor of TFT after controlling for ZAP-70, IGHV, or CD38 (all P < 0.001). 
      Among patients with 13q- plus one other FISH abnormality, concomitant 13q- 
      appeared to attenuate the shorter survival associated with 17p- (P = 0.019). The 
      clinical implications of 13q- in CLL appear more complex than originally 
      appreciated.
FAU - Van Dyke, Daniel L
AU  - Van Dyke DL
AD  - Division of Laboratory Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 
      55905, USA. vandyke.daniel@mayo.edu
FAU - Shanafelt, Tait D
AU  - Shanafelt TD
FAU - Call, Timothy G
AU  - Call TG
FAU - Zent, Clive S
AU  - Zent CS
FAU - Smoley, Stephanie A
AU  - Smoley SA
FAU - Rabe, Kari G
AU  - Rabe KG
FAU - Schwager, Susan M
AU  - Schwager SM
FAU - Sonbert, Jessica C
AU  - Sonbert JC
FAU - Slager, Susan L
AU  - Slager SL
FAU - Kay, Neil E
AU  - Kay NE
LA  - eng
GR  - R01 CA095241/CA/NCI NIH HHS/United States
GR  - R01 CA095241-07/CA/NCI NIH HHS/United States
GR  - CA95241/CA/NCI NIH HHS/United States
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20091106
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Chromosome Deletion
MH  - Chromosomes, Human, Pair 13/*genetics
MH  - Chromosomes, Human, Pair 17/genetics
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/*genetics/therapy
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Survival Analysis
MH  - Time Factors
PMC - PMC2866061
MID - NIHMS163763
COIS- Conflict-of-Interest disclosure: The authors declare no conflict of interests.
EDAT- 2009/11/10 06:00
MHDA- 2010/06/30 06:00
PMCR- 2011/02/01
CRDT- 2009/11/10 06:00
PHST- 2009/11/10 06:00 [entrez]
PHST- 2009/11/10 06:00 [pubmed]
PHST- 2010/06/30 06:00 [medline]
PHST- 2011/02/01 00:00 [pmc-release]
AID - BJH7982 [pii]
AID - 10.1111/j.1365-2141.2009.07982.x [doi]
PST - ppublish
SO  - Br J Haematol. 2010 Feb;148(4):544-50. doi: 10.1111/j.1365-2141.2009.07982.x. 
      Epub 2009 Nov 6.